Study: GLP-1 drugs enhance strength, reverse ageing in mice

Study: GLP-1 drugs enhance strength, reverse ageing in mice

GLP-1 signaling in the brain offers anti-aging potential. Recent research highlights GLP-1 receptor agonism as a weight-neutral method to enhance strength and organ resilience with age. This pathway may present a viable means of counteracting systemic aging, demanding further investigation into its mechanisms and applications.


New multi-omic data reveal that glucagon-like peptide-1 (GLP-1) signaling in the brain can drive body-wide rejuvenation, offering a potential weight-neutral path to preserving strength and organ resilience with age. This research, published in the journal Cell Metabolism, evaluates whether GLP-1 receptor (GLP-1R) agonism counteracts aging across various organs without significant weight impact. The study also explores its hypothalamic dependence and compares its effects with mammalian target of rapamycin (mTOR) inhibition.

By 2050, one in six people will be over 65, living longer with chronic conditions. Aging alters metabolism, immunity, and gene regulation, diminishing strength and resilience. Current interventions like calorie restriction and mTOR inhibition show promise but raise safety and feasibility concerns. GLP-1 biology, which connects appetite and metabolism, is already targeted in clinical settings. The study suggests GLP-1R agonism meets criteria for an effective anti-aging strategy but requires further investigation to understand its systemic benefits in a weight-neutral context.

Male C57BL/6 mice were studied, with no female inclusion noted as a limitation. Mice received intraperitoneal injections of the GLP-1R agonist exenatide or phosphate-buffered saline (PBS) from 11 months of age for 30 weeks. Motor function was assessed, revealing that exenatide improved grip strength and rotarod performance without significant weight loss. Transcriptomic analysis across multiple organs showed reversal of age-related changes, particularly in metabolically active tissues.

In a second cohort, hypothalamic GLP-1R knockdown weakened systemic anti-aging effects, underscoring the brain’s role in coordinating benefits. Comparisons with rapamycin revealed overlapping anti-aging signatures, although GLP-1R agonism showed a distinct central nervous system route for systemic change. The study indicates that GLP-1R agonism could support strategies to preserve strength and organ resilience with age, though it did not assess lifespan extension and was limited to male subjects.


Stories for you


  • Delta passes million vehicle charging mark

    Delta passes million vehicle charging mark

    Delta says its chargers have powered one million industrial vehicles globally. The company’s installed base now spans AGVs, AMRs, forklifts, and heavier-duty vehicles in round-the-clock logistics operations.


  • Cementex targets HVAC safety with insulated toolkit

    Cementex targets HVAC safety with insulated toolkit

    Cementex is targeting HVAC work with an insulated toolkit. The nine-piece set is aimed at technicians working around energised equipment and remains configurable for customer-specific service requirements.